RTsafe was established in 2014 to commercialize the internationally patented PseudoPatient® idea. The basic component of which is to build an exact replica of patient’s head to be radiotherapy treated and tested, before his/her actual treatment, aiming to verify and secure the safety and quality of life of the patient treated. PseudoPatient® incorporating point or film detectors has already been awarded (R&D100 award, 1st prize in MIT Enterprise Forum).
In July 2019, our proposal gained the seal-of-excellence under the SME Inst. ph. II. Furthermore, more than 70 related studies have already been published by the RTsafe team members.
Additionally, the PseudoPatient® idea has attracted radiotherapy equipment manufacturers as a means of testing, commissioning and quality assurance (machine QA) tool (using treatment-simulation plans).
The production line is currently based in Athens utilizing 3D printing and CNC technologies.
Since the completion of the 1st funding round in 2017 RTsafe Holding Ltd. was established in Ireland which owns 100% its two subsidiaries: RTsafe P.C. (Greece), and RTsafe Inc. (USA). Company shareholders own shares only of the Holding entity, which owns 100% of the IP rights of the International Patent of the PseudoPatient® offering. Company has achieved to gain – apart from various awards - FDA 510(k) clearance for the US market and is ISO13485 and ISO9001 certified.